|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Here are some ideas of strength and diversity along with yield.
We need some cooperation from China and oil. Please.
Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.
U.S. stocks lost earlier gains to fall into the red after another selloff in crude oil prices pressured the energy sector.
And four other things you need to know now.
Shares of Alphabet could have another banner year after surging 54 percent in 2015.
Investors are praying that 2016 starts on an uplifting note.
Look for 2015's record run of mergers and acquisitions to continue.
Good morning, all! Bret Jensen here! I'm happy to be sitting in for Doug Kass once again on the Daily Diary. We'll find out today whether the market can make it three days in a row on the upside, as November has opened with a big rally despite so-so...
Biotech's pipeline includes a cancer drug that's close to approval.
The S&P 500 volatility index fell more than 16%.
Energy names fare well.
Futures jump on hopes for a later Fed rate hike.
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.
Utilities and technology names led the way lower, resulting in an overall modest decline.
Baxalta (BXLT) shares were on watch after the company rejected an unsolicited offer from Shire (SHPG).
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
A company that divides itself can unlock value.
U.S. stocks opened flat Tuesday. The latest Paychex survey on small business shows steady, continued growth.
Beyond Greece, Puerto Rico and the June jobs report, Investors should also be aware of a big number of corporate spin-offs this week.